Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary
1The University of Kansas Medical Center and Hospital, 39th and Rainbow Blvd., Kansas City, KS 66106, USA. csolomon@kumc.edu
Abstract:
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Angina IV: Management
